Letter by Groothof et al Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial"

Circulation. 2022 Jul 12;146(2):e5-e6. doi: 10.1161/CIRCULATIONAHA.122.060263. Epub 2022 Jul 11.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Clinical Trials as Topic
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Hypoglycemic Agents* / therapeutic use
  • Proline / therapeutic use
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use

Substances

  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors
  • efpeglenatide
  • Proline